ACCEPTED. Yanjun Li 1. M. Hong Nguyen 2,3,4. Harmut Derendorf 1. Shaoji Cheng 2. *Cornelius J. Clancy 2,3
|
|
- Tyrone Maxwell
- 6 years ago
- Views:
Transcription
1 AAC Accepts, published online ahead of print on 21 May 2007 Antimicrob. Agents Chemother. doi: /aac Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Measurement of voriconazole activity against Candida albicans, C. glabrata and C. parapsilosis isolates using time-kill methods validated by high performance liquid chromatography Yanjun Li 1 M. Hong Nguyen 2,3,4 Harmut Derendorf 1 Shaoji Cheng 2 *Cornelius J. Clancy 2,3 1 Department of Pharmaceutics, University of Florida College of Pharmacy, Departments of 2 Medicine and 3 Molecular Genetics and Microbiology, University of Florida College of Medicine, and 4 North Florida/South Georgia Veterans Health System, Gainesville, FL * Corresponding author: Cornelius J. Clancy, MD University of Florida College of Medicine Box JHMHC 1600 SW Archer Rd. Gainesville, FL Ph: Fax: clancyn@medicine.ufl.edu Running title: HPLC validates voriconazole time-kill against Candida Key words: Candida parapsilosis/candida glabrata/candida spp./time-kill/high performance liquid chromatography (HPLC) Word counts: Abstract: 50 Text: 997 1
2 Abstract. We developed an HPLC assay to validate time-kill and post-antifungal effect (PAFE) experiments for voriconazole against C. albicans, C. glabrata and C. parapsilosis isolates. Voriconazole exerted prolonged fungistatic activity but no PAFE at concentrations achievable in human sera. HPLC confirmed that experiments were conducted at the desired steady-state voriconazole concentrations. 2
3 Voriconazole is a triazole agent that inhibits ergosterol synthesis by blocking the action of 14α-demethylase. The drug is fungistatic and exhibits no post-antifungal effect (PAFE) against Candida albicans (1, 3-5, 7, 9). Time-kill and PAFE data are limited against C. glabrata (1, 7), and do not exist against C. parapsilosis isolates. Moreover, standard timekill and PAFE methodologies, although widely used, have not been validated for voriconazole or other antifungals by direct measurements of drug concentrations. In this study, we developed an high performance liquid chromatography (HPLC) assay to validate the results of time-kill and PAFE experiments for voriconazole against C. albicans reference strains (ATCC and SC5314), and C. glabrata and C. parapsilosis bloodstream isolates (2 each). The MICs of all isolates were within the susceptible range, as measured by E-test and microdilution methods (Table 1) (10, 11). For time-kills and PAFEs, colonies from 48-hour cultures on Sabouraud dextrose agar (SDA) were suspended in 9 ml sterile water (2, 7). One microliter of a 0.5 McFarland suspension was added to 10 ml of RPMI 1640 medium with or without voriconazole (0.25-, 1-, 4-, and 16 MIC), and the solution was incubated at 35 C with agitation. The maximal voriconazole concentration in these experiments was 3.04 µg/ml (16 MIC for C. glabrata #1). For time-kills, 100 µl from each solution was serially diluted at desired time points and plated on SDA plates for colony enumeration (0, 2, 4, 8, 12, 24, 36, 48, 60 and 72 hours). For PAFEs, Candida cells were collected after 1 hour of incubation, washed three times, and resuspended in warm RPMI medium (9 ml); colonies were enumerated at desired time periods. Voriconazole exhibited dose-response effects against all 3
4 Candida isolates during time-kill experiments (Figure 1; Table 1), as higher concentrations resulted in greater growth inhibition or killing. The range of maximal growth inhibition of isolates at concentrations of 1- and 4 MIC was to 2.78-log and to 2.99-log, respectively, compared to controls (Table 1). At 16 MIC, the range of maximal growth inhibition was to 4.15-log. Voriconazole did not demonstrate PAFEs (data not shown). Voriconazole at 16 MIC was fungicidal against C. parapsilosis #2, reducing the starting inoculum by 2.21-log at 24 hours (fungicidal defined as > 2-log reduction of starting inoculum). Although kills did not achieve fungicidal levels for other isolates, voriconazole at 4- and 16 MIC reduced starting inocula of C. glabrata #2 and C. parapsilosis # 1 (Table 1). Of note, voriconazole was consistently fungistatic at 1- to 16 MIC, and the effect persisted for 72 hours. Indeed, maximal inhibition of the four C. albicans and C. glabrata isolates at 4- and 16 MIC (compared to starting inocula) was not evident until 48 to 72 hours. The two C. parapsilosis isolates, on the other hand, were maximally inhibited by 24 to 36 hours. The time-kill curves of the C. parapsilosis isolates also differed from the other isolates at early time points. The C. parapsilosis isolates at 4- and 16 MIC were inhibited from entering exponential growth, and dose-response effects were clearly evident by 8 hours. The growth of C. albicans and C. glabrata isolates in the presence of voriconazole did not differ from controls during early exponential phase, but dose-response effects became increasingly apparent as exponential growth continued (8 to 24 hours). 4
5 In our HPLC protocol for measuring voriconazole concentrations during time-kill and PAFE experiments, a mm analytic column with mm guard cartridge (Hichrom, Reading, UK) was packed with 5 µm Kromasil at 25 C in an Agilent 1100 Series apparatus (6, 8). Mobile phase acetonitrile-ammonium phosphate buffer (ph 6.0; 0.04 M; 1:1 v:v) was degassed by filtration through a 0.45 µm nylon filter under vacuum; the flow rate was 0.8 ml/min. Voriconazole concentrations were determined from peak areas detected by UV absorption at 255 nm with an 8.2 minute retention time. For each isolate, we tested RPMI medium containing at least one concentration of voriconazole between 1- and 16 MIC. Samples were diluted with 2 volumes of acetonitrile-ammonium phosphate buffer, centrifuged at full speed in a microcentrifuge for 10 minutes, and supernatants (200 µl) applied to the column. The maximum sensitivity was µg/ml, and the method was linear over a range of µg/ml (r ). In each instance, we confirmed that voriconazole concentrations remained constant throughout the duration of time-kill experiments (Figure 2), and the drug was fully removed during PAFE experiments (data not shown). Our findings conclusively demonstrate that voriconazole exerts prolonged fungistatic activity against C. albicans, C. glabrata and C. parapsilosis at concentrations that are achievable in human sera with routine dosing (median average and maximum voriconazole plamsa concentrations in clinical trials are 2.51 and 3.79 µg/ml, respectively) (12). Our findings are potentially relevant clinically, since certain C. parapsilosis isolates exhibit 5
6 diminished susceptibility to echinocandin antifungals and C. glabrata isolates can develop resistance to fluconazole and other antifungal agents. Although voriconazole caused >2-log kill of one C. parapsilosis isolate, further studies will be needed to accurately define the extent to which the drug might be fungicidal against clinical isolates. To our knowledge, this is the first study to verify standard time-kill and PAFE methodologies by directly measuring drug concentrations. We describe a simple and reproducible HPLC method that has a broad, clinically relevant dynamic range and does not require internal standards. The sensitivity of voriconazole measurements within liquid media was greater than that previously reported for human or guinea pig plasma ( and 5 10 µg/ml, respectively) (6, 8). Based on our findings, we can assume that previous studies of azoles that showed fungistatic anti-candidal activity and no PAFEs were conducted under the conditions of steady-state drug concentrations assumed by investigators. This demonstration is crucial as efforts to use pharmacodynamic data to develop optimal antifungal treatment strategies move forward. In particular, HPLC methods will be essential to the design of dynamic in vitro models to assess the pharmacodynamics of voriconazole and other agents prior to the achievement of steady-state conditions. The authors thank Dr. Vipul Kumar for his advice in developing the HPLC assay. Experiments were conducted in Dr. Clancy s laboratory at the North Florida/South Georgia Veterans Health System, Gainesville, FL. This project was supported by the Medical Research Service of the Department of Veterans Affairs. It was conducted as part of the 6
7 University of Florida Mycology Research Unit (NIH PO1 AI to Drs. Nguyen and Clancy). Dr. Clancy has received research support from Pfizer. 7
8 References. 1. Canton E, Peman J, Gobernado M, Viudes A, and Espinel-Ingroff A Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 49: Clancy CJ, Huang H, Cheng S, Derendorf H, and Nguyen MH Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother 50: Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, and Piccolomini R In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 48: Ernst EJ, Yodoi K, Roling EE, and Klepser ME Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 46: Espinel-Ingroff A In vitro antifungal activities of anidulafungin and 8
9 micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20: Gage R, and Stopher DA A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 17: Klepser ME, Malone D, Lewis RE, Ernst EJ, and Pfaller MA Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 44: , MacCallum DM, Whyte JA, and Odds FC Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49: Manavathu EK, Cutright JL, and Chandrasekar PH Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 42: NCCLS Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2 nd ed. NCCLS document M27-A2. NCCLS, Wayne, PA. 11. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, 9
10 Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, Sheehan DJ, Troke P, Walsh TJ, and Warnock DW Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44: Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, and Andes D Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:
11 Table 1. Voriconazole MICs and time-kill data against Candida isolates. Isolate MIC (µg/ml) Maximum log-kill (24 h) 1x MIC 4x MIC 16x MIC C. albicans ATCC Maxiumum log-kill (24-48 h) 1x MIC 4x MIC 16x MIC Maximum log-kill (>48 h) 1x MIC 4x MIC 16x MIC C. albicans SC C. glabrata C. glabrata C. parapsilosis C. parapsilosis Time-kill data are presented as the maximum difference in the growth of the control isolate (grown in the absence of voriconazole) and that of the isolate in the presence of various voriconazole concentrations at 24 hours, 24 to 48 hours, and > 48 hours, respectively. Maximum growth inhibition of each isolate at given concentrations is in bold. MICs as determined by E-test. MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (CLSI document M27-A2) were within 2-fold agreement. 11
12 1e+8 Ctrl 0.25*MIC 1*MIC 4*MIC 16*MIC C. albicans ATCC e+8 C. glabrata 1 1e+7 1e+7 N_CFU/mL 1e+6 1e+5 1e Time_hr 1e+8 1e+7 1e+6 1e+5 C. glabrata 2 Fig. 1. Time-kill curves for voriconazole against Candida isolates. Representative curves are presented for each isolate. Experiments were performed in duplicate, without significant differences in results. 1e+6 1e+8 1e+7 1e+6 1e+5 1e+4 1e+3 C. parapsilosis 2 1e+4 1e
13 120 C. glabrata 1 %Voriconazole Concentration Time_hr Fig.2. Measurements of voriconazole concentrations in culture media by HPLC. Representative data for 48 hour time-kill experiment against C. glabrata #1 are presented. Concentrations of voriconazole against each Candida isolate were 85% of the starting concentration at all time points. 13
Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1207 1212 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Influence of Test Conditions on Antifungal Time-Kill
More informationESCMID Online Lecture Library. by author
Eric DANNAOUI ESCMID Postgraduate Education Course 20-22 June 2013, Sibiu Antifungal susceptibility testing and detection of resistance: principles and practices Unité de Parasitologie-Mycologie, Laboratoire
More informationApproximately 20% of the responding CLSI membership whose hospitals had greater than 200 beds was performing antifungal testing.
Vol. 28 No. 14 Replaces M27-A2 Vol. 22 No. 15 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard Third Edition This document addresses the selection and
More informationfor Antifungal Susceptibility Testing of Yeast Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1994, p. 1992-1996 0095-1137/94/$00+0 Copyright C 1994, American Society for Microbiology Vol., No. 8 Evaluation of a Novel Colorimetric Broth Microdilution Method
More informationfor Antifungal Susceptibility Testing of Yeast Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1994, p. 1992-1996 0095-1137/94/$00+0 Copyright C 1994, American Society for Microbiology Vol., No. 8 Evaluation of a Novel Colorimetric Broth Microdilution Method
More informationfor Antifungal Susceptibility Testing of Yeast Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1994, p. 1992-1996 0095-1137/94/$00+0 Copyright C 1994, American Society for Microbiology Vol., No. 8 Evaluation of a Novel Colorimetric Broth Microdilution Method
More informationCase. Case. Case. Case. Reference lab AST. Nelesh Govender, NICD 2013/03/08. Candida species: Antifungal susceptibility testing in 2013
Nelesh Govender, NICD 13/3/8 se ndida species: Antifungal susceptibility testing in 13 Nelesh Govender National Institute for Communicable Diseases and University of the Witwatersrand, Johannesburg Elderly
More informationtesting for the daily routine?
What is the role of in vitro antifungal susceptibility testing for the daily routine? ESCMID, Rome 2010 Cornelia Lass-Flörl Medical University Innsbruck Faculty disclosure Invited speaker: Pfizer, Gilead,
More informationFLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA SPECIES BY DISC DIFFUSION AND AGAR DILUTION METHOD
FLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA SPECIES BY DISC DIFFUSION AND AGAR DILUTION METHOD Supriya Tankhiwale, Sunita Gajbhiye, Rajaram Powar 1. Associate Professor, Department of Microbiology, Government
More informationCut-off Values and Species-Specific Breakpoints 12/19/2016
Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. 1 Laboratories and Professor of Laboratory Medicine
More informationHours: Comparison of the Rapid Susceptibility Assay with the Clinical and Laboratory. Standards Institute s Microbroth Dilution Assay AFFILIATION
JCM Accepts, published online ahead of print on 21 October 2009 J. Clin. Microbiol. doi:10.1128/jcm.01306-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationChapter 2 Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods
Chapter 2 Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods Annette W. Fothergill Abstract Antifungal susceptibility testing has become an important tool for
More informationAntifungal PK/PD Made Simple. David Andes, MD University of Wisconsin
Antifungal PK/PD Made Simple David Andes, MD University of Wisconsin PK/PD Concept Serum Drug Concentration Peak:MIC AUC:MIC Ratio Time Above MIC MIC Time Hypothesis and Concept There is an optimal drug
More informationStandardization of Antifungal Susceptibility Variables for a Semiautomated Methodology
JOURNAL OF CLINICAL MICROBIOLOGY, July 2001, p. 2513 2517 Vol. 39, No. 7 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.7.2513 2517.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationInfluence of Glucose Supplementation and Inoculum Size on Growth Kinetics and Antifungal Susceptibility Testing of Candida spp.
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2001, p. 525 532 Vol. 39, No. 2 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.2.525 532.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Influence
More informationACCEPTED. Species-Specific Differences in the Susceptibility of Biofilms Formed by. University Medical School, Gwangju, Korea
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationIdentification of Candida inconspicua clinical isolates and testing of fluconazole, amphotericin B, flucytosine and caspofungin susceptibility
Identification of Candida inconspicua clinical isolates and testing of fluconazole, amphotericin B, flucytosine and caspofungin susceptibility Ph.D. theses László Majoros Department of Medical Microbiology,
More informationSHORT THESIS FOR DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.)
SHORT THESIS FOR DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) The paradoxical growth of Candida albicans, C. dubliniensis, C. krusei and C. tropicalis strains in the presence of high concentration caspofungin
More informationDisk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole
J Microbiol Immunol Infect. 2009;42:148-153 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole Sai-Cheong
More informationReceived 2 August 1995/Returned for modification 10 October 1995/Accepted 18 January 1996
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1996, p. 842 847 Vol. 34, No. 4 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Fluconazole and Amphotericin B Antifungal Susceptibility Testing
More informationIn vitro Antifungal Activity of Isavuconazole and Comparators Against Rare Yeast Pathogens
AAC Accepts, published online ahead of print on 21 June 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00685-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEUCAST DEFINITIVE DOCUMENT
EUCAST DEFINITIVE DOCUMENT 10.1111/j.1469-0691.2007.01935.x EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts Subcommittee
More informationCandida biofilm. José Garnacho Montero Hospital Universitario Virgen del Rocío Sevilla. Spain
Candida biofilm José Garnacho Montero Hospital Universitario Virgen del Rocío Sevilla. Spain Introduction Candidemia is frequently associated with the biofilm growth of Candida organisms on medical devices
More informationEmpfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium
Empfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium EUCAST reloaded 6.0 Follow-up Workshop 23.03.2017 Cornelia Lass-Flörl Division of
More informationComparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2007, p. 3529 3533 Vol. 45, No. 11 0095-1137/07/$08.00 0 doi:10.1128/jcm.00826-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison
More informationAntifungal Susceptibility testing: New trends. Abstract: Amina Mostafa Abdel Aal, Mohamed M. Taha*, Noha El-Mashad and Walaa El-Shabrawy
Antifungal Susceptibility testing: New trends Amina Mostafa Abdel Aal, Mohamed M. Taha*, ha El-Mashad and Walaa El-Shabrawy Egyptian Dermatology Online Journal 3 (1): 1, June, 2007 Departments of: Clinical
More informationPreliminary Evaluation of a Semisolid Agar Antifungal Susceptibility Test for Yeasts and Molds
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 537 541 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Preliminary Evaluation of a Semisolid
More informationCandida species remain the most common cause of invasive fungal infections, with. crossm
PHARMACOLOGY crossm SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies Bernard Scorneaux, a David Angulo, a Katyna Borroto-Esoda, a Mahmoud Ghannoum, b Michael Peel, a Stephen Wring a Scynexis,
More informationANTIFUNGAL SUSCEPTIBILITY TESTING
MYCOLOGY QAP UPDATE ANTIFUNGAL SUSCEPTIBILITY TESTING Sarah Kidd: National Mycology Reference Centre, SA Pathology Deb Walker, Elizabeth Haremza, Arthur Morris: RCPAQAP sarah.kidd@sa.gov.au @thefunguskidd
More informationACCEPTED. In vitro interactions of micafungin with amphotericin B against. clinical isolates of Candida spp.
AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM
Antifungal sensitivity testing using VITEK 2 Dr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM VITEK 2 Systems The VITEK 2 System is intended for the automated identification and susceptibility
More informationPossible mechanisms of the antifungal activity of fluconazole in combination with terbinafine against Candida albicans
http://informahealthcare.com/phb ISS 388-29 print/iss 744-56 online Editor-in-Chief: John M. Pezzuto Pharm Biol, Early Online: 5! 24 Informa Healthcare USA, Inc. DOI:.39/38829.24.988 ORIGIAL PAPER Possible
More informationUse of Fluorescent Probes To Determine MICs of Amphotericin B and Caspofungin against Candida spp. and Aspergillus spp.
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2005, p. 3788 3792 Vol. 43, No. 8 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.8.3788 3792.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationMulticenter Evaluation of Four Methods of Yeast Inoculum Preparation
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1988, p. 1437-1441 0095-1137/88/081437-05$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 26, No. 8 Multicenter Evaluation of Four Methods of Yeast
More informationEffects of Caspofungin against Candida guilliermondii and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2006, p. 2719 2727 Vol. 50, No. 8 0066-4804/06/$08.00 0 doi:10.1128/aac.00111-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Effects
More informationReceived 5 September 2006/Returned for modification 17 October 2006/Accepted 21 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 698 706 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01840-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative
More informationCorrelation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2006, p. 819 826 Vol. 44, No. 3 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.3.819 826.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Correlation
More informationA Combination Approach to Treating Fungal Infections
University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Publications Pharmaceutical Sciences 11-23-2015 A Combination Approach to Treating Fungal Infections Sanjib K. Shrestha University of Kentucky,
More informationCencountered problem in hospitalised
Utility of Chrom Medium for Antifungal Susceptibility Testing of Candida Species Against Fluconazole and Voriconazole in Resource Constrained Settings Shashir Wanjare, Rupali Suryawanshi, Arati Bhadade,
More informationReceived 5 June 2009/Returned for modification 31 July 2009/Accepted 23 October 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2010, p. 154 161 Vol. 48, No. 1 0095-1137/10/$12.00 doi:10.1128/jcm.01096-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Antifungal Susceptibility
More informationAntifungal Resistance: Focus on Candida species
Antifungal Resistance: Focus on Candida species Peter G. Pappas, MD, FACP Professor of Medicine and Director, MSG Division of Infectious Diseases University of Alabama at Birmingham Birmingham, AL, USA
More informationCaspofungin in Combination with Amphotericin B against Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2007, p. 941 945 Vol. 51, No. 3 0066-4804/07/$08.00 0 doi:10.1128/aac.00880-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Caspofungin
More informationReceived 14 November 2010/Returned for modification 27 December 2010/Accepted 13 March 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2011, p. 3031 3035 Vol. 55, No. 6 0066-4804/11/$12.00 doi:10.1128/aac.01569-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. In Vitro
More informationNovel Fluorescent Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida albicans
JOURNAL OF CLINICAL MICROBIOLOGY, July 2001, p. 2708 2712 Vol. 39, No. 7 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.7.2708 2712.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationSusceptibility testing in Aspergillus species complex
REVIEW 10.1111/1469-0691.12514 Susceptibility testing in Aspergillus species complex C. Lass-Fl orl Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria Abstract
More informationIn vitro Activity of Caspofungin against Planktonic and Sessile Candida sp. Cells
Polish Journal of Microbiology 2006, Vol. 55, No 2, 133 137 In vitro Activity of Caspofungin against Planktonic and Sessile Candida sp. Cells ANNA SEREFKO, BEATA CHUDZIK and ANNA MALM Department of Pharmaceutical
More informationEffect of uvastatin and pravastatin, HMG-CoA reductase inhibitors, on uconazole activity against Candida albicans
J. Med. Microbiol. Ð Vol. 51 2002), 105±109 # 2002 Society for General Microbiology ISSN 0022-2615 MYCOLOGY Effect of uvastatin and pravastatin, HMG-CoA reductase inhibitors, on uconazole activity against
More informationComparison of four reading methods of broth microdilution based on the Clinical and Laboratory Standards Institute M27-A3 method for Candida spp.
Oct. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 5 335 45 Comparison of four reading methods of broth microdilution based on the Clinical and Laboratory Standards Institute M27-A3 method for Candida spp.
More informationGentian Violet Exhibits Activity against Biofilms formed by Oral Candida isolates Obtained from HIV-infected Patients
AAC Accepts, published online ahead of print on 28 March 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01601-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationNoha El-Mashad, Mona F. Foad, Niveen Saudy, Dalia A. Salem. Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt.
Brazilian Journal of Microbiology (2012): 266-273 ISSN 1517-8382 SUSCEPTIBILITY TESTS OF OROPHARYNGEAL CANDIDA ALBICANS FROM EGYPTIAN PATIENTS TO FLUCONAZOLE DETERMINED BY THREE METHODS Noha El-Mashad,
More informationAntifungal Suceptibility Testing : Guidelines to Practical approach. Dr Deepti Rawat
Antifungal Suceptibility Testing : Guidelines to Practical approach Dr Deepti Rawat Introduction Increase incidence of fungal infections Increase in immunosuppressive states Increasing evidence of invasive
More informationEffects of Temperature on Anti-Candida Activities of Antifungal Antibiotics
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1993, p. 685-691 Vol. 37, No. 4 66-484/93/4685-7$2./ Copyright 1993, American Society for Microbiology Effects of Temperature on Anti-Candida Activities of Antifungal
More informationIn Vitro Interactions between Tacrolimus. Determined by Different Methods. Shujuan Sun, Yan Li, Qiongjie Guo, Changwen Shi, Jinlong Yu and Lin Ma
REFERENCES CONTENT ALERTS In Vitro Interactions between Tacrolimus and Azoles against Candida albicans Determined by Different Methods Shujuan Sun, Yan Li, Qiongjie Guo, Changwen Shi, Jinlong Yu and Lin
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.276
More informationIn vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes
Medical Mycology June 2006, 44, 357362 In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes D. A. SANTOS & J. S. HAMDAN Department of Microbiology,
More informationCharacterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1999, p. 2116 2120 Vol. 43, No. 9 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Characterization and Quantitation
More informationIn Vivo Pharmacokinetics and Pharmacodynamics of APX001 against. Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
AAC Accepted Manuscript Posted Online 29 January 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.02542-17 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 In Vivo Pharmacokinetics
More informationPharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), using an In Vivo Murine Invasive Candidiasis Model
AAC Accepts, published online ahead of print on 15 December 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04445-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Pharmacodynamic
More informationMinimum Inhibitory Concentration (MIC) Assay for Antifungal Drugs
Minimum Inhibitory Concentration (MIC) Assay for Antifungal Drugs Jinglin L. Xie 1, Sheena D. Singh-Babak 2 and Leah E. Cowen 2* 1 Molecular Genetics, University of Toronto, Toronto, Canada; 2 Department
More informationAn In Vitro Study of Sequential Fluconazole/Caspofungin Treatment. against Candida albicans Biofilms
AAC Accepts, published online ahead of print on 11 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01745-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationIn vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method
Tropical Biomedicine 27(2): 200 207 (2010) In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method Madhavan, P. 1, Jamal, F. 1*, Chong, P.P. 2 and Ng,
More informationMethod for the determination of broth dilution minimum Inhibitory concentrations of antifungal agents for yeasts
EUCAST DEFINITIVE DOCUMENT E.DEF 7.3 Method for the determination of broth dilution minimum Inhibitory concentrations of antifungal agents for yeasts M. C. Arendrup 1, J Guinea 2, M. Cuenca-Estrella 3,
More informationJAC A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
Journal of Antimicrobial Chemotherapy (1999) 43, 477 481 JAC A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp. Estrella
More informationVoriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012
Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version 1.0 20 May 2012 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationOptimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1426 1433 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02273-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Optimizing
More informationon September 27, 2018 by guest
AAC Accepts, published online ahead of print on 26 August 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01032-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Comparison
More informationMICROBIOLOGY AND INVASIVE FUNGAL INFECTION. Javier Pemán, MD, PhD. Mycology Unit, Hospital Univ. La Fe Valencia (Spain)
MICROBIOLOGY Mycology Unit, Hospital Univ. La Fe Valencia (Spain) AND INVASIVE FUNGAL INFECTION Javier Pemán, MD, PhD What tools we can offer to optimize antifungal treatment? From lab Bench to Bedside:
More informationIn Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1057 1061 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activities of Terbinafine against Cutaneous
More informationIn Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1057 1061 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activities of Terbinafine against Cutaneous
More informationInvestigation of Association between Slime Production by Candida Spp and Susceptibility to Fluconazole and Voriconazole
Original Research Article Tropical Journal of Pharmaceutical Research October 2013; 12 (5): 821-825 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University
More informationTHIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY AGAINST CANDIDA SPECIES
STUDIA UBB CHEMIA, LXI, 3, Tom I, 2016 (p. 117-123) (RECOMMENDED CITATION) Dedicated to Professor Luminița Silaghi-Dumitrescu on the occasion of her 65 th anniversary THIAZOLE DERIVATIVES WITH ANTIFUNGAL
More informationOutline. Introduction. Broth and Agar testing methods Automated susceptibility testing. Aims of antimicrobial susceptibility testing:
Outline Microbiology Technical Workshop Broth and Agar testing methods Automated susceptibility testing Dr Tan Yen Ee Registrar Singapore General Hospital 25th Sept 2013 Introduction Broth testing methods
More informationApproaches to Development of Analytical Method for Combination Products Containing Fluconazole
Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance 2014; 5(1); 1-5 Research Article ISSN 0975 9506 Approaches to Development of Analytical Method for Combination
More informationUtility of the Germ Tube Test for the Identification of Candida albicans Directly from Positive Blood Culture Bottles. ACCEPTED
JCM Accepts, published online ahead of print on August 00 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationWell diffusion for antifungal susceptibility testing
International Journal of Infectious Diseases (2004) 8, 39 45 Well diffusion for antifungal susceptibility testing S. Magaldi a, S. Mata-Essayag a, *, C. Hartung de Capriles a, C. Perez a, M.T. Colella
More informationBiofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
More informationPhenotypic characterization of Candida isolates obtained from non respiratory clinical specimens from superspeciality tertiary care center in Mumbai
Original article: Phenotypic characterization of Candida isolates obtained from non respiratory clinical specimens from superspeciality tertiary care center in Mumbai Dr. Dhruv K. Mamtora, Dr Sanjith Saseedharan,
More informationPharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 137 142 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.137 142.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationRapid identification of Candida glabrata in Candida bloodstream infections
Journal of Medical Microbiology (2007), 56, 1639 1643 DOI 10.1099/jmm.0.47406-0 Rapid identification of Candida glabrata in Candida bloodstream infections Nicholas Foster, Charlotte Symes, Richard Barton
More informationPrevalence of albicans and non-albicans candiduria in a Malaysian medical centre
1375 ORIGINAL ARTICLE Prevalence of albicans and non-albicans candiduria in a Malaysian medical centre Chuan Hun Ding, Asrul Abdul Wahab, Najihan Abdul Samat Muttaqillah, Mohd Nizam Tzar Abstract Objective:
More informationReceived 4 May 2011/Returned for modification 20 July 2011/Accepted 23 July 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2011, p. 4880 4887 Vol. 55, No. 10 0066-4804/11/$12.00 doi:10.1128/aac.00621-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Pharmacodynamics
More informationDealer Bulletin. Re: OPTIM 33TB; 3 Minute Fungicidal Claim. OPTIM 33TB Contact Times* To: All Authorized SciCan Dealers Canada
www.scicancanada.ca Dealer Bulletin To: All Authorized SciCan Dealers Canada Date: June 29, 2017 Re: OPTIM 33TB; 3 Minute Fungicidal Claim Dear SciCan Dealer; OPTIM 33TB has a fungicidal contact time;
More informationVL-2397: A Novel Approach to Treat Life-Threatening Invasive Fungal Infections
VL-2397: A Novel Approach to Treat Life-Threatening Invasive Fungal Infections 8th Congress on Trends in Medical Mycology October 8, 2017 Safe Harbor Statement This presentation contains forward-looking
More informationABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18
M26-A ISBN 1-56238-384-1 September 1999 ISSN 0273-3099 Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline Volume 19 Number 18 Arthur L. Barry, Ph.D. William A. Craig,
More informationStudy on the comparative activity of echinocandins on murine gut colonization by Candida albicans
Medical Mycology, 2015, 53, 597 602 doi: 10.1093/mmy/myv028 Advance Access Publication Date: 14 May 2015 Original Article Original Article Study on the comparative activity of echinocandins on murine gut
More informationComparative evaluation of the Vitek 2 yeast susceptibility test and CLSI. broth microdilution reference method for antifungal susceptibility testing
JCM Accepts, published online ahead of print on 14 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.00952-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationmycoses In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans Na Guo, 1,3 * Guanghui
More informationT-2307 Shows Efficacy in a Murine Model of Candida glabrata Infection despite In Vitro Trailing Growth Phenomena
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2010, p. 3630 3634 Vol. 54, No. 9 0066-4804/10/$12.00 doi:10.1128/aac.00355-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. T-2307
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1998, p Vol. 36, No. 10. Copyright 1998, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1998, p. 3007 3012 Vol. 36, No. 10 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Detection of Candida dubliniensis
More informationAssessment of Serum 1,3-β-D-glucan as a Measure of Disease Burden in Invasive Pulmonary Aspergillosis
Assessment of Serum 1,3-β-D-glucan as a Measure of Disease Burden in Invasive Pulmonary Aspergillosis Nathan P. Wiederhold University of Texas at Health Science Center at San Antonio University of Texas
More informationSusceptibility kinetic profile of Candida albicans biofilm on latex silicone surfaces with antifungal azoles
Current Research in Environmental & Applied Mycology 8(6): 564 571 (2018) ISSN 2229-2225 www.creamjournal.org Article Doi 10.5943/cream/8/6/1 Susceptibility kinetic profile of Candida albicans biofilm
More informationEfficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2010, p. 1055 1059 Vol. 54, No. 3 0066-4804/10/$12.00 doi:10.1128/aac.01445-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Efficacy
More informationQuantification of CDR1 Gene Expression in Fluconazole Resistant Candida Glabrata Strains Using Real-time PCR
Iran J Public Health, Vol. 46, No.8, Aug 2017, pp.1118-1122 Original Article Quantification of CDR1 Gene Expression in Fluconazole Resistant Candida Glabrata Strains Using Real-time PCR Shadi SHAHROKHI¹,
More informationNON ALBICANS CANDIDA SPECIES: ITS ISOLATION PATTERN, SPECIES DISTRIBUTION, VIRULENCE FACTORS AND ANTIFUNGAL SUSCEPTIBILITY PROFILE
RESEARCH ARTICLE NON ALBICANS CANDIDA SPECIES: ITS ISOLATION PATTERN, SPECIES DISTRIBUTION, VIRULENCE FACTORS AND ANTIFUNGAL SUSCEPTIBILITY PROFILE Sachin Deorukhkar, Santosh Saini Department of Microbiology,
More informationUniversity of Wisconsin, Departments of Microbiology and Immunology 1 and Highland Ave. Madison, WI phone (608)
JCM Accepts, published online ahead of print on 12 January 2011 J. Clin. Microbiol. doi:10.1128/jcm.02273-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationACCEPTED. * Corresponding author. Mailing address: Istituto di Malattie Infettive e Medicina Pubblica,
AAC Accepts, published online ahead of print on 7 April 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00130-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationProfessor, Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2
Curr Med Mycol, 26 Mar, 2(): 24-29 Article Original Susceptibility pattern of Candida albicans isolated from Iranian patients to antifungal agents Badiee P, Badali H 2, Diba K 3, Ghadimi Moghadam A 4,
More informationSIOPI MARIA, M.Sc. Clinical Chemistry
Personal information Date of birth: 20/09/1984 Place of birth: Athens, Greece Work address: Clinical Microbiology Laboratory, Attikon University General Hospital, 1 Rimini Str., Haidari, Athens 124 62,
More informationBioPhysics Assay Laboratory, Inc. ٠ 80 Webster Street ٠ Worcester MA ٠ Phone (508) ٠ Fax (508) ٠
Introduction In this report, we describe and present the performance characteristics of an immunoassay (ELISA) method to measure the concentration of iohexol in collected samples to obtain a mgfr value.
More information